Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine stockpiles as health officials and experts worry the highly contagious H5N1 influenza virus tearing through poultry farms and cattle herds could spread to humans . Getty Images Moderna said the U.S. government funds will bankroll "late-stage development for an mRNA-based vaccine" against H5 influenza virus to en ...

The CHMP's recommendation will now be reviewed by the European Commission (EC) and a final decision is expected shortly. If authorized, mResvia will be Moderna's second approved product in the region. The above news comes just a few days after Moderna suffered a major setback after the U.S. Centers for Disease Control and Prevention (CDC) revised their recommendation for the use of RSV vaccines for the upcoming respiratory virus season. This recommendation is based on data from data from the phase III Conqu ...

Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials. Undoubtedly, most of the drug candidates will run into a wall at some point in the trials. It can be a long and grueling move from Phase I to the finish line. For the biotech firms that can advance past all clinical trials and prove that a treatment is both safe and effective, the rewards could have the po ...

An 18-month analysis of follow-up data showed that Moderna's RSV vaccine was just about 49.9% effective in preventing RSV-LRTD. This is significantly lower compared with the 80.9% vaccine efficacy achieved by the vaccine at a follow-up period of 3.7 months. Image Source: Zacks Investment Research This efficacy rate was also significantly lower compared with GSK's Arexvy and Pfizer's Abrysvo, both of which are also approved for similar use by the FDA. These companies also presented data on their respective R ...

The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks that have dropped in the double digits over the past few years are coronavirus vaccine giants Moderna (MRNA -11.01%) and Pfizer (PFE -2.04%). Adria Cimino (Moderna): Moderna entered the coronavirus vaccine market with a splash in early pandemic days, becoming a vaccine leader along with Pfizer. The vaccine, Moderna' ...

Loading... In the presentation slides to the U.S. agency, Moderna Inc MRNA shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up. Vaccine efficacy in the infection with more than two symptoms was 50.3% and 49.9% in disease with three or more symptoms. Efficacy of a single dose of GSK Plc's GSK Arexvy over two calendar years showed vaccine efficacy of 73.3% (W/o season covariate) and 78.6% in severe infection. Last year, GSK's Arexvy and Pfizer's Abrysv ...

Moderna Today Moderna -5.20 (-3.58%) ▼ Price Target $129.02 Biotechnology firm Moderna Inc. NASDAQ: MNRA made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innovative treatments. The company continues expanding its treatments for various diseases and illnesses, including cardiovascular disease, cancer, and other rare diseases. Moderna has been working on personalized cancer vaccines that will enable a cancer p ...

The company's post-pandemic prospects are getting brighter. Moderna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. That's why the company's stock skyrocketed in the earlier days of the pandemic. It's also why its shares have lagged over the past three years -- its COVID-19 vaccine sales dropped off a cliff. However, the biotech has been looking to move beyond this therapeutic area. It recently earned approval for a vaccine for the respiratory syncytial virus (RSV). Even more rec ...

Moderna(MRNA) announced positive results from the pivotal phase III NextCOVE study evaluating mRNA1283, its next-generation refrigerator-stable COVID-19 vaccine, in individuals aged 12 years and older. Image Source: Zacks Investment Research The study achieved its primary efficacy endpoint, demonstrating the non-inferior vaccine efficacy of mRNA1283 against COVID-19 when compared to mRNA-1273.222, Moderna's previously approved bivalent Omicron BA.4/BA.5-targeting COVID-19 vaccine. A higher efficacy was also ...

Moderna intends to engage with regulatory authorities for regulatory submissions. Management intends to market mRNA-1083 by 2025. Year to date, Moderna's shares have surged 49.4% against the industry's 5.9% fall. Image Source: Zacks Investment Research Last year, Moderna provided a positive interim update from a phase III immunogenicity study (P303) on mRNA-1010 in older adults. Data from the study showed that mRNA-1010 elicited higher immune responses across all four A and B strains of influenza than GSK's ...